IRF4 and Miyoshi myopathy: Although BETi are known to regulate the expression of oncogenes and regulators of MM survival (e.g. MYC, IRF4)28,33, sensitization to other anti-MM targeted therapies35–37 and the recognition by immune effector cells38, the characterization of their anticancer molecular targets is still incomplete.